Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter adjusted profit per share of $12.56 compared to $23.42, prior year. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $10.03, for the quarter. Analysts' estimates typically exclude special items.
Net profit was $1.20 billion or $10.50 per share compared to $2.23 billion or $19.69 per share, prior year.
Revenue declined 31% to $3.41 billion. Total revenues excluding REGEN-COV and Ronapreve was $3.02 billion, up 14%. Analysts on average had estimated $3.13 billion in revenue. EYLEA U.S. net sales decreased 3% to $1.50 billion.
For the full year 2022, non-GAAP net income per share was $44.98, compared to $74.35, last year. Full year revenues decreased 24% to $12.17 billion. Excluding REGEN-COV and Ronapreve, revenues increased 17%.
"In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets," said Leonard Schleifer, President and CEO of Regeneron.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News